Product Description
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Adimmune
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Influenza, Human|Kidney Failure, Chronic
Phase 3: Influenza, Human
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| FLU09002 | N/A |
Completed |
Influenza, Human |
2010-04-01 |
2019-03-19 |
Treatments |
|
| FLU09001 | N/A |
Completed |
Influenza, Human |
2010-04-01 |
2019-03-19 |
Treatments |
|
| 200912031R | N/A |
Unknown status |
Influenza, Human |
2010-02-01 |
2019-03-19 |
Treatments |
|
| 2016-001557-41 | P3 |
Completed |
Influenza, Human |
2017-09-05 |
2025-05-06 |
Treatments |
|
| ADIMQIS20160328 | P3 |
Completed |
Influenza, Human |
2017-07-12 |
2019-09-25 |
Primary Endpoints|Treatments |
|
| A-BR-101-139 | P4 |
Unknown status |
Influenza, Human|Kidney Failure, Chronic |
2014-06-01 |
2019-03-20 |
Treatments |
|
| FLU12T13A | P4 |
Completed |
Influenza, Human |
2012-08-01 |
2019-03-19 |
Treatments |
|
| FLU11T12P | P4 |
Completed |
Influenza, Human |
2012-06-01 |
2019-03-19 |
Treatments |
|
| BR-100-086 | P4 |
Unknown status |
Influenza, Human |
2012-03-01 |
2019-03-19 |
||
| FLU10T11C | P4 |
Completed |
Influenza, Human |
2011-09-01 |
2019-03-19 |
Treatments |
|
| FLU10T11B | P4 |
Completed |
Influenza, Human |
2011-04-01 |
2019-03-19 |
Treatments |
|
| FLU10T11A | P4 |
Completed |
Influenza, Human |
2010-08-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/10/2023 |
News Article |
Clover Provides Updates on Business and R&D Pipeline Development |
|
05/23/2023 |
News Article |
Clover Expands Sales and Distribution Network for Upcoming Quadrivalent Seasonal Influenza Vaccine Launch in China |
|
02/19/2023 |
News Article |
Clover Enters into Exclusive Agreement to Commercialize Quadrivalent Seasonal Influenza Vaccine in Mainland China |